Prognostic value of N–terminal pro B–type natriuretic peptide and troponin I in children with dengue shock syndrome

Abstract

Objective: To investigate the contribution of N-terminal pro B-type natriuretic peptide (NT-pro BNP) and troponin I to mortality in children with dengue shock syndrome.

Methods: A longitudinal study was conducted on children with dengue shock syndrome in a hospital in southern Vietnam. Detailed clinical histories, physical examinations, and laboratory parameters, including NT-pro BNP and troponin I, were recorded. A comparison between survival and non-survival was carried out to identify factors influencing mortality.

Results: A total of 107 patients with a median age of 9 years were included in the study. Among them, 63.6% (68/107) presented with compensated shock, 36.4% (39/107) had hypotensive shock, 23.4% (25/107) required mechanical ventilation, and 12.1% (13/107) died. The NT-pro BNP levels were 3.9 pmol/L (IQR: 1.9, 10.3) and 15.2 pmol/L (5.8, 46.3), while the median high sensitivity troponin I levels were 20 pg/L (6, 95) and 62 pg/L (12, 325) at the first and second measurements, respectively. The mortality group exhibited higher rates of hypotensive shock, prolonged shock, lactate levels, liver damage, NT-pro BNP, and troponin I levels. Hypotensive shock (OR 12.96, 95% Cl 2.70-62.30, P=0.004), prolonged shock (OR 39.40, 95% CI 6.68-232.70, P<0.001), AST > 1 000 IU/L (OR 9.50, 95% CI 2.63-34.34, P=0.041), and NT-pro BNP > 7 pmol/L (OR 44.40, 95% CI 5.44-362.20, P=0.001) were identified as predictive factors for mortality in dengue shock syndrome.

Conclusions: The NT-pro BNP level could serve as a potential biomarker for predicting mortality in children with dengue shock syndrome.

Keywords

Dengue shock syndrome / Cardiac enzyme / NT-pro BNP / Troponin I

References

[1] Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. Nat Rev Dis Primers 2016; 2(1): 16055.

[2] World Health Organization. WHO guidelines approved by the Guidelines Review Committee. Dengue: guidelines for diagnosis, treatment, prevention and control. New edition. Geneva: World Health Organization; 2009.

[3] World Health Organization. Dengue situation updates 2023 WHO regional office for the western Pacific. 2023. [Online]. Available from: https://apps.who.int/iris/handle/10665/365676. [10 November 2023].

[4] Farrukh AM, Ganipineni VDP, Jindal U, Chaudhary A, Puar RK, Ghazarian K, et al. Unveiling the dual threat: Myocarditis in the spectrum of dengue fever. Curr Probl Cardiol 2023; 49(1 Pt A): 102029.

[5] Katrukha IA, Katrukha AG. Myocardial injury and the release of troponins I and T in the blood of patients. Clin Chem 2021; 67(1): 124-130.

[6] Chaulin AM. Cardiac troponins metabolism: From biochemical mechanisms to clinical practice (literature review). Int J Mol Sci 2021; 22(20): 10928.

[7] Pagel-Langenickel I. Evolving role of natriuretic peptides from diagnostic tool to therapeutic modality. Adv Exp Med Biol 2018; 1067: 109-131.

[8] Alcidi G, Goffredo G, Correale M, Brunetti ND, Iacoviello M. Brain natriuretic peptide biomarkers in current clinical and therapeutic scenarios of heart failure. J Clin Med 2022; 11(11): 3192.

[9] Islam S, Khan MAS, Badal MFA, Khan MZI, Gozal D, Hasan MJ. Clinical and hematological profiles of children with dengue residing in a non-endemic zone of Bangladesh. PLoS Negl Trop Dis 2022; 16(10): e0010847.

[10] Preeprem N, Phumeetham S. Paediatric dengue shock syndrome and acute respiratory failure: A single-centre retrospective study. BMJ Paediatr Open 2022; 6(1): e001578.

[11] Nguyen Phung NT, Kieu Pham TT, Tuan Tran D. Respiratory distress associated with dengue hemorrhagic fever on paediatric patients: Learning from a provincial hospital in southern Vietnam. Arch Pharma Pract 2019; 10(3): 92-97.

[12] Kurnia B, Suryawan IWB. The association between obesity and severity of dengue hemorrhagic fever in children at Wangaya General Hospital. Open Access Maced J Med Sci 2019; 7(15): 2444-2446.

[13] Neeraja M, Iakshmi V, Teja VD, Lavanya V, Priyanka EN, Subhada K, et al. Unusual and rare manifestations of dengue during a dengue outbreak in a tertiary care hospital in South India. Arch Virol 2014; 159(7): 1567-1573.

[14] Menwal U, Rawat A, Rawat A, Chandar V. Cardiac manifestations of dengue fever in pediatrics age group. Indian J Child Health 2020; 7(9): 363-365.

[15] Mansanguan C, Hanboonkunupakarn B, Muangnoicharoen S, Huntrup A, Poolcharoen A, Mansanguan S, et al. Cardiac evaluation in adults with dengue virus infection by serial echocardiography. BMC Infect Dis 2021; 21(1): 940.

[16] Miranda CH, Borges Mde C, Matsuno AK, Vilar FC, Gali LG, Volpe GJ, et al. Evaluation of cardiac involvement during dengue viral infection. Clin Infect Dis 2013; 57(6): 812-819.

[17] Rao R, Nayak S, Pandey AK, Kamath SU. Diagnostic performance of C-reactive protein level and its role as a potential biomarker of severe dengue in adults. Asian Pac J Trop Med 2020; 13(8): 358-365.

[18] Atmaja GT, Buntubatu S, Wijaya CS, Sudarmadi ANP, Laksono IS, Indrawanti R, et al. Comparison of cardiac marker profiles in dengue myocarditis. J Med Sci (Berkala Ilmu Kedokteran) 2023; 55(1). doi: 10.19106/JMedSci005501202304.

[19] Bhatt M, Soneja M, Farooqui FA, Singla P, Vikram NK, Biswas A, et al. Myocarditis in admitted patients with dengue fever. Infection 2020; 48(6): 899-903.

[20] Phung NTN, Vo DM, Le TN, Doan TT. Total serum cortisol level is low in children with severe dengue shock syndrome. Trop Biomed 2021; 38(3): 396-402.